Sartorius Stedim Biotech: Transitory Effects Overshadow Secular Growth

Frank Fischer of Shareholder Value Management presented his investment thesis on Sartorius Stedim Biotech (France: DIM) at Best Ideas 2024.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

First name:

Last name:

Email address:

City / state / country:

Company:

How did you hear about MOI Global? Select Member referral Staff This website Media / Internet Other

If referral, please provide member's name:

Which of the following applies most closely to you? Select Investment Firm - Head Investment Firm - Analyst or PM Institutional Allocator - Firm C-Level Executive Institutional Allocator - Firm Employee Family Office - Head or Co-Owner Family Office - Employee Non-Investment Firm - C-Level Executive Non-Investment Firm - Employee Other

How do you hope to add value to the community?

Leave this field empty if you're human:

About the instructor:

Frank Fischer, born in 1964, is the CEO of Shareholder Value Management AG, where he is Chief Investment Officer (CIO). Frank is also a board member of Shareholder Value Beteiligungen AG. Until the end of 2005, Frank was managing director of Standard & Poor’s Fund Services (formerly Micropal GmbH) and was responsible for investment fund information and ratings.

After completing his training as a banker (Bankkaufmann) at the Hessische Landesbank, he studied economics at the Goethe University of Frankfurt where he finished with his degree in business administration (Diplom Kaufman).

Frank is married and has two children. He and his wife Julia are the founders and directors of the non-profit foundation Stiftung Starke Lunge (www.starkelunge.de).